Compare KRNY & ENTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KRNY | ENTA |
|---|---|---|
| Founded | 1884 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 459.7M | 486.3M |
| IPO Year | 2014 | 2012 |
| Metric | KRNY | ENTA |
|---|---|---|
| Price | $7.27 | $12.88 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $8.00 | ★ $20.40 |
| AVG Volume (30 Days) | ★ 276.2K | 174.6K |
| Earning Date | 04-22-2026 | 05-11-2026 |
| Dividend Yield | ★ 6.07% | N/A |
| EPS Growth | ★ 130.22 | 29.93 |
| EPS | ★ 0.30 | N/A |
| Revenue | $2,580,000.00 | ★ $102,814,000.00 |
| Revenue This Year | $3.89 | $5.91 |
| Revenue Next Year | $17.52 | N/A |
| P/E Ratio | $24.17 | ★ N/A |
| Revenue Growth | ★ 36.00 | 16.48 |
| 52 Week Low | $5.45 | $4.09 |
| 52 Week High | $8.50 | $17.15 |
| Indicator | KRNY | ENTA |
|---|---|---|
| Relative Strength Index (RSI) | 34.37 | 41.11 |
| Support Level | $7.22 | $12.09 |
| Resistance Level | $8.42 | $15.52 |
| Average True Range (ATR) | 0.22 | 0.74 |
| MACD | -0.06 | -0.19 |
| Stochastic Oscillator | 9.56 | 11.04 |
Kearny Financial Corp is a federally-chartered stock savings bank. The bank is engaged in the business of attracting deposits from the general public in New Jersey and New York, and using these deposits, together with other funds, to originate or purchase loans for its portfolios and invest in securities. The bank's loan portfolio is chiefly comprised of loans collateralized by commercial and residential real estate. The bank's primary source of income is net interest income.
Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.